Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1922 1
1947 1
1949 2
1954 1
1967 1
1969 1
1970 1
1973 2
1974 1
1975 1
1983 3
1986 1
1987 2
1988 1
1990 1
1991 1
1993 3
2004 1
2005 1
2006 1
2007 2
2008 2
2009 5
2010 4
2011 8
2012 6
2013 7
2014 3
2015 11
2016 8
2017 9
2018 17
2019 31
2020 35
2021 35
2022 30
2023 30
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Results by year

Filters applied: . Clear all
Page 1
What causes hidradenitis suppurativa ?-15 years after.
Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos-Bourboulis EJ, Fabbrocini G, Frew JW, Fujita H, González-López MA, Guillem P, Gulliver WPF, Hamzavi I, Hayran Y, Hórvath B, Hüe S, Hunger RE, Ingram JR, Jemec GBE, Ju Q, Kimball AB, Kirby JS, Konstantinou MP, Lowes MA, MacLeod AS, Martorell A, Marzano AV, Matusiak Ł, Nassif A, Nikiphorou E, Nikolakis G, Nogueira da Costa A, Okun MM, Orenstein LAV, Pascual JC, Paus R, Perin B, Prens EP, Röhn TA, Szegedi A, Szepietowski JC, Tzellos T, Wang B, van der Zee HH. Zouboulis CC, et al. Among authors: frew jw. Exp Dermatol. 2020 Dec;29(12):1154-1170. doi: 10.1111/exd.14214. Exp Dermatol. 2020. PMID: 33058306 Free article. Review.
Target molecules for future hidradenitis suppurativa treatment.
Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, Jemec GBE, Del Marmol V, Marzano AV, Nikolakis G, Sayed CJ, Tzellos T, Wolk K, Prens EP. Zouboulis CC, et al. Among authors: frew jw. Exp Dermatol. 2021 Jun;30 Suppl 1:8-17. doi: 10.1111/exd.14338. Exp Dermatol. 2021. PMID: 34085329 Free article. Review.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Among authors: frew j. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Free article. Clinical Trial.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.
Cellular neurothekeoma.
Stewart T, Cachia A, Frew J. Stewart T, et al. Among authors: frew j. Int J Womens Dermatol. 2021 Jul 31;7(5Part B):835-837. doi: 10.1016/j.ijwd.2021.07.011. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35028394 Free PMC article. No abstract available.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Brand DH, et al. Among authors: frew j. Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17. Lancet Oncol. 2019. PMID: 31540791 Free PMC article. Clinical Trial.
The value of case reports in pharmacovigilance.
Garcia-Doval I, Segovia E, Hunter H, Frew J, Naldi L. Garcia-Doval I, et al. Among authors: frew j. Br J Dermatol. 2020 Nov;183(5):795-796. doi: 10.1111/bjd.19504. Br J Dermatol. 2020. PMID: 33135791 No abstract available.
232 results